The U.S. Food and Drug Administration (FDA) has ordered the recall of Hologic’s BioZorb 3D bioabsorbable markers, implantable devices designed to mark soft tissue locations during medical procedures, following reports of adverse patient outcomes. The company has voluntarily withdrawn the product from the market after the FDA identified safety concerns linked to patient complications during use.
Key takeaways
- Hologic has recalled BioZorb 3D bioabsorbable markers used to identify soft tissue landmarks in imaging and surgery
- The recall follows documented reports of patient complications associated with the implantable devices
- Healthcare providers should immediately cease use and contact Hologic regarding existing inventory and patient follow-up protocols
- The FDA continues to monitor for additional adverse events related to the product
What are BioZorb markers and their intended use?
BioZorb 3D bioabsorbable markers are small implantable devices designed to precisely mark locations in soft tissue, particularly in breast tissue during surgical procedures and imaging-guided interventions. According to the FDA’s official recall notice, these markers are intended to remain in tissue temporarily before gradually breaking down and being absorbed by the body. The devices have been used in clinical settings to help surgeons and radiologists identify specific lesions or treatment sites that require intervention.
Implantable Device Recall Process and Timeline
FDA classification and manufacturer responsibility in medical device recalls
Source: FDA Medical Device Recall Process | Georgian Medical Journal News
Safety concerns driving the recall
The FDA’s recall documentation indicates that adverse events reported to the agency raised serious questions about the marker’s biocompatibility and absorption characteristics. According to the agency’s statement, complications documented in patient cases suggested that the device may not behave as originally designed during implantation or the absorption phase. The specific nature of these complications—whether related to inflammatory response, incomplete absorption, or tissue migration—underscores the critical importance of pre-market safety validation for bioabsorbable implants.
This recall reflects broader quality and safety challenges in the medical device sector. As outlined in recent FDA safety guidance, manufacturers are responsible for conducting rigorous post-market surveillance and must report adverse events promptly to regulators. The decision to recall BioZorb 3D markers demonstrates the FDA’s commitment to protecting patients when safety signals emerge, even after a device has received regulatory clearance.
Hologic has voluntarily withdrawn BioZorb 3D bioabsorbable markers from the market following FDA identification of safety concerns linked to patient complications during clinical use.
— U.S. Food and Drug Administration, Medical Device Recall Notice
Implications for clinical practice and patient care
The recall has immediate implications for hospitals, surgical centers, and imaging facilities that stock or use BioZorb 3D markers. According to the FDA’s recall guidance, healthcare providers must immediately cease use of remaining inventory and implement protocols to identify and contact patients who received the implant. This includes establishing follow-up schedules to monitor for delayed or unexpected complications that may not have manifested at the time of implantation.
For clinicians, the recall underscores the necessity of maintaining awareness of quality and safety alerts from regulatory agencies and device manufacturers. Surgeons and interventional radiologists should review their current alternatives for soft-tissue marking and ensure that replacement devices carry clear evidence of safety validation. The incident also highlights the importance of informed consent, particularly when novel bioabsorbable materials are used in clinical practice.
What this means
Frequently asked questions
What should I do if I had a BioZorb 3D marker implanted?
Contact the healthcare facility where your procedure was performed and provide your name and date of procedure. Your care team will review your records to confirm whether you received the recalled device. If you did, your provider will schedule follow-up appointments to monitor for any complications. Report any unusual symptoms—such as pain, swelling, redness, or imaging findings—to your physician immediately.
What alternative devices can be used instead of BioZorb 3D markers?
Several alternative soft-tissue marking devices are available and have well-established safety profiles. These include titanium clips, radioactive seeds (iodine-125), and other bioabsorbable markers with longer clinical track records. Your surgeon will select the most appropriate alternative based on the specific clinical indication, tissue type, and imaging requirements for your procedure.
How does the FDA monitor medical device safety after products reach the market?
The FDA operates a post-market surveillance system called MedWatch, through which healthcare providers, manufacturers, and patients report adverse events. The agency reviews these reports to identify safety signals and may issue recalls, safety communications, or impose restrictions on device use. Manufacturers are required by law to monitor their products and report serious adverse events to the FDA within specific timeframes.
The BioZorb 3D recall serves as a reminder that no medical device, regardless of regulatory approval status, is risk-free. Ongoing vigilance by manufacturers, healthcare systems, and regulatory agencies remains essential to protect patient safety. Healthcare providers should remain engaged with updates from the FDA’s medical device safety database and quality and safety alerts to ensure their institutions maintain current knowledge of device recalls and emerging safety concerns.
Source: FDA Medical Device Recall Notice: Hologic BioZorb 3D Bioabsorbable Markers
Was this article helpful?
Related Coverage
